TONGUE RETAINING DEVICE SALES BUSINESS PLAN

I. Executive Summary

Company Description

The company name reflects clinical respiratory care and was chosen to signal trust and medical credibility. We are a U.S.-based medical supply company launching in 2026 that operates in the sleep health and durable medical equipment industry. Our primary business is designing, manufacturing, and selling modern, non-invasive alternatives to traditional CPAP machines for sleep apnea patients. Our key products are silent, portable tongue retaining devices produced in a specialized medical office and lab using advanced injection molding and clean room technology. One-liner: we deliver silent, portable respiratory solutions for sleep apnea.

We sell directly to consumers via e-commerce and through professional medical distribution to sleep clinics and durable medical equipment providers. Main activities include device R&D, clinical fit and testing, in-house injection molding, clean-room assembly, professional training for clinicians, and customer support. What sets us apart is the combination of medical-grade manufacturing, a non-invasive product that improves comfort and adherence, and a dual-channel go-to-market approach. Target customers are adult sleep apnea patients seeking non-CPAP alternatives and the clinicians who treat them. Short-term goal: launch product and establish initial sales channels in 2026. Long-term goal: scale distribution nationally and become a recognized clinical option for sleep-disordered breathing.

Problem

Millions of Americans have obstructive sleep apnea that causes daytime fatigue and raises long-term cardiovascular risk. Continuous positive airway pressure (CPAP) is clinically effective but shows low real-world adherence because devices are bulky, noisy, and intrusive; patients and partners report disrupted sleep and discomfort. There is a clear gap for effective, non-electrical interventions tailored to mild-to-moderate cases that improve comfort and adherence.

The market lacks silent, portable, non-invasive respiratory options produced in regulated medical facilities and distributed both direct-to-consumer and through medical channels; this gap leaves patients with suboptimal treatment, ongoing safety risks from fatigue, and unmet needs for comfortable, adherence‑friendly devices. One-liner: current CPAP solutions fail many patients, so comfortable, non-electrical alternatives are needed.

Solution

Millions of Americans with obstructive sleep apnea cannot tolerate bulky, noisy CPAP machines, creating a need for a silent, comfortable, non-electric alternative. Our solution is non-invasive oral appliances that hold the tongue forward to keep the airway open without hoses, masks, or motors—simple, clinical-grade devices that improve compliance and reduce health risk.

Product line: a Basic model for standard use, an Adjustable model for customized patient positioning, and a compact Travel model that requires no power. All devices use medical-grade polymers and biocompatible resins to meet clinical standards, delivering silent, portable therapy for home and travel. One-liner: silent, comfortable, non-electric tongue-forward therapy that fits everyday life.

Mission Statement

We eliminate barriers to effective sleep apnea treatment by delivering comfortable, silent, and portable oral appliances that improve long-term health and quality of life for millions of Americans. We commit to clinical excellence, regulatory integrity, and patient-centered innovation in every product and process. Our goal is to become the leading alternative to CPAP therapy in the United States by making restful sleep simple and accessible.

Key Success Factors

Breakeven in month 1 of the 2026 launch; high-growth, high-return profile.

• Deliver immediate profitability; breakeven in month 1.
• Scale manufacturing capacity from 38,000 to 243,000 units annually.
• Secure strong intellectual property and an FDA clearance pathway.
• Diversify revenue: high-value appliances plus recurring consumables.
• Generate exceptional returns: 173.76% IRR and 74.29% ROE.

Financial Summary

Concise financial snapshot: rapid breakeven and strong margin expansion support growth from $7.048M in Year 1 to $43.200M in Year 5 with disciplined 8% marketing and a lean expert team.

Financial requirements: minimum cash $1,133,000 (required Jan-26); payback: 1 month; anticipated returns: IRR 173.76% and ROE 74.29%.

Strong cash generation and short payback make the financial outlook highly favorable.

Funding Requirements

The company requires $1,133,000 in initial funding to establish minimum cash, cover early CapEx and pay first-year fixed costs; breakeven is Jan-26 and payback is one month.